On the stock market since 1986, it operates in the world of health and science. It has 5,200 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year). Red columns mark years that ended in a loss.
The gap is $664.9M. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
On our five-subject report card, HNGR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HNGR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.